187 related articles for article (PubMed ID: 36970914)
1. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Hauser RA; Ondo WG; Zhang Y; Bowling A; Navia B; Pappert E; Isaacson SH;
J Parkinsons Dis; 2023; 13(3):403-414. PubMed ID: 36970914
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Hauser RA; Isaacson S; Clinch T;
Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
[TBL] [Abstract][Full Text] [Related]
3. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine (Apokyn) for advanced Parkinson's Disease.
Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S;
Ther Adv Neurol Disord; 2023; 16():17562864231209240. PubMed ID: 37954918
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
9. Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine.
Axelsson P; Thörn SE; Lövqvist A; Wattwil L; Wattwil M
Can J Anaesth; 2006 Apr; 53(4):370-4. PubMed ID: 16575035
[TBL] [Abstract][Full Text] [Related]
10. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting.
Gottlieb M; Carlson JN; Peksa GD
Cochrane Database Syst Rev; 2022 May; 5(5):CD013860. PubMed ID: 35588093
[TBL] [Abstract][Full Text] [Related]
12. Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Clin Neuropharmacol; 1996 Jun; 19(3):193-201. PubMed ID: 8726538
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three preclinical models for nausea and vomiting assessment.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
[TBL] [Abstract][Full Text] [Related]
14. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
15. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
16. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
Mulhall JP; Bukofzer S; Edmonds AL; George M;
Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
18. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
20. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy.
Jones JM; Qin R; Bardia A; Linquist B; Wolf S; Loprinzi CL
J Palliat Med; 2011 Jul; 14(7):810-4. PubMed ID: 21554125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
